(Q43101832)

13 November 2017

The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts (English)

1 reference

13 November 2017

0 references

Yusuf Yilmaz

1

1 reference

PubMed ID

20387080

13 November 2017

language of work or name

1 reference

13 April 2010

1 reference

Journal of Gastroenterology

13 November 2017

1 reference

13 November 2017

45

1 reference

13 November 2017

7

1 reference

13 November 2017

782-783

1 reference

Gene expression in human NAFLD.

13 November 2017

1 reference

12 December 2020

Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.

1 reference

12 December 2020

Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes

1 reference

12 December 2020

Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins

1 reference

12 December 2020

A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins".

1 reference

12 December 2020

Scavenger receptors that recognize advanced glycation end products

1 reference

12 December 2020

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

1 reference

12 December 2020

Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation

1 reference

12 December 2020

Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings

1 reference

12 December 2020

10.1007/S00535-010-0251-3

Identifiers

DOI

1 reference

13 November 2017

1 reference

PubMed ID

20387080